Avacta Group
- 29th November 2022
A clinical stage oncology company developing new cancer therapies continues to move its AVA6000 treatment towards completion of Phase I trials
Client: Total Market Solutions
Client: Total Market Solutions
Client: Total Market Solutions
Client: Total Market Solutions
Client: Total Market Solutions
Client: Total Market Solutions
Client: Total Market Solutions
Client: Total Market Solutions
Client: Total Market Solutions
Client: Total Market Solutions
With acknowledgement to Unsplash for many of the images used in this section